Historique de carrière de Mann Muhsin
Anciens postes connus de Mann Muhsin
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MEDICENNA THERAPEUTICS CORP. | Directeur Technique/Scientifique/R&D | 12/05/2021 | 17/01/2022 |
HUYA Bioscience International LLC
 HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/04/2019 | 01/04/2020 |
| HALOZYME THERAPEUTICS, INC. | Corporate Officer/Principal | 01/03/2016 | 01/03/2019 |
Formation de Mann Muhsin
| University of Baghdad | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Canada | 2 |
| Irak | 2 |
Opérationnelle
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MEDICENNA THERAPEUTICS CORP. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
HUYA Bioscience International LLC
HUYA Bioscience International LLC Pharmaceuticals: MajorHealth Technology HUYA Bioscience International LLC develops biopharmaceutical products. It sources pharmaceutical innovation originating in China for global development in international markets. It's lead immune-oncology lead product, HBI-8000, already approved in China, is now in registration trials in Japan and Korea for lymphoma and in clinical trials in the U.S. for various solid tumor indications in combination with the checkpoint inhibitor nivolumab. The company was founded by Mireille Gillings in 2004 and is headquartered in San Diego, CA. | Health Technology |
- Bourse
- Insiders
- Mann Muhsin
- Expérience
